Lento Bio, Inc

LAFAYETTE, NY · Founded 2022 · CIK 0001979322 · Medtech

Ophthalmic eye drop formulation to restore lens elasticity and reverse presbyopia

lentobio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.0M
1 Form D · May 2023
40 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,000,000
Form D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1265QCMedchain LLC——
1266CytoTronics, Inc.—$14M
1267NanoSpy, Inc.——
1268Lento Bio, Inc—$5.0M
1269MIMETAS US, INC——
1270Whisker Labs, Inc.—$11M
1271QUICKSILVER BIOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Kris BarnesDirector · Executive Officer
  • Kelsey MoodyDirector
  • Kenneth ScottDirector

Patents

USPTO · 0 granted of 2
  • N-pivaloylcysteine Derivatives For The Treatment Of Presbyopiaapplication
  • N-pivaloylcysteine Derivatives For The Treatment Of Presbyopiaapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.